bioMérieux S.A.. (2/27/19). "Press Release: bioMérieux – 2018 Financial Results".

	Organisation	bioMérieux S.A. (Euronext: BIM)
	Group	Mérieux (Group)
	Product	molecular diagnostics
	Person	Mérieux, Alexandre (Mérieux 201712– CEO at bioMérieux before Deputy CEO before VP Industrial Microbiology)

> Organic sales growth of 9.9% for full-year 2018:
>> €2,421 million in sales
>> Up 5.8% as reported
>> Solid fourth-quarter performance, with organic growth of more than 10%

> Improvement in contributive operating income before non-recurring items, which came to €361 million or close to 15% of sales, despite unfavorable currency effect

> 2019 financial targets:
>> Organic growth in sales of between 7.0% and 8.5%, at constant exchange rates and scope of consolidation
>> Contributive operating income before non-recurring items of between €385 million and €400 million, at current exchange rates

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “In 2018, bioMérieux recorded very satisfactory results and stepped up the deployment of its immunoassay strategy, with Astute and Hybiome transactions. In 2019, bioMérieux intends to maintain its sales dynamics and to improve its operational and financial performance, for the benefit of clients and patients, true to its continued commitment to serve public health."

Download [ https://www.biomerieux.com/sites/corporate/files/news-event-press-release/biomerieux_pr_2018_results.pdf ]

Record changed: 2019-04-24

More documents for Mérieux (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com